Healthcare

Adhere+ Announces Acceptance of Two Scientific Posters at the 2025 American Society of Pain & Neuroscience (ASPN) Annual Conference

Posters highlight Remote Therapeutic Monitoring (RTM) implementation insights and outcomes from more than 2.2 million patient-reported observations WASHINGTON, July 1,...

Accelerating Measurable Improvement Through Actionable Insights: Health Catalyst Announces the Release of 10 AI-Integrated Data Toolkits on Databricks Marketplace

SALT LAKE CITY, July 1, 2025 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and...

HealingMaps and Advanced Behavioral Strategies Launch Healing Health Alliance, the First Group Purchasing Organization (GPO) Exclusively for Ketamine, Psychedelic Medicine and TMS Clinics

Miami, Florida--(Newsfile Corp. - July 1, 2025) - HealingMaps, the leading directory for ketamine, psychedelic-assisted therapy, and TMS clinics, and...

Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis

The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007 in patients with moderate-to-severe atopic dermatitisTopline data expected in...

error: Content is protected !!